ASIT reports positive outcome from Phase III trial of gp-ASIT+ in allergic rhinitis by pollen

Belgian clinical-stage biopharmaceutical firm ASIT Biotech has reported positive results from its Phase III clinical trial of gp-ASIT+ for the treatment of patients with grass pollen-induced allergic rhinitis.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news